Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 7/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.33 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797111 | 1.00 | CACNA1B (0.42) | CACNA1BHSD17B3P2RX4HTR7ATM | |
| SCHEMBL4798827 | 0.97 | HSD17B3 (0.40) | CACNA1BHSD17B3P2RX4HTR7ATM | |
| SCHEMBL4798836 | 0.97 | HSD17B3 (0.40) | CACNA1BHSD17B3P2RX4HTR7ATM | |
| SCHEMBL4797984 | 0.85 | HSD17B3 (0.38) | HSD17B3 | |
| SCHEMBL4797972 | 0.85 | HSD17B3 (0.38) | HSD17B3 | |
| SCHEMBL4802970 | 0.85 | HSD17B3 (0.48) | CACNA1BHSD17B3ATM | |
| SCHEMBL4799318 | 0.84 | HSD17B3 (0.45) | HSD17B3TGFBR1 | |
| SCHEMBL4799309 | 0.84 | HSD17B3 (0.45) | HSD17B3TGFBR1 | |
| SCHEMBL4798294 | 0.82 | HSD17B3 (0.48) | CACNA1BHSD17B3 | |
| SCHEMBL4798186 | 0.78 | HSD17B3 (0.46) | HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | CACNA1B 4310/4885HSD17B3 1/4885P2RX4 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.